HM

Hirenkumar Mansukhlal Marvaniya

Active Director Director DIN 11227919
DIN 11227919 First appointment Aug 2025 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2025
Shareholding value β€’β€’β€’β€’ Premium profile

About Hirenkumar Mansukhlal Marvaniya

Data last updated:

Hirenkumar Mansukhlal Marvaniya is a Director at Chynops Pharma Private Limited (since 2025). The company operates in Pharma.

DIN 11227919
Primary Designation Director
Industry Pharma
First Appointment 04 Aug 2025
Oldest Company Age 1 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Chynops Pharma Private Limited U21000GJ2025PTC165833
Director04 Aug 20252025Active

Board colleagues of Hirenkumar Mansukhlal Marvaniya

Directorship timeline

Open interactive timeline →
Chynops Pharma Private Limited
Premium access

Shareholding and investment profile for Hirenkumar Mansukhlal Marvaniya

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Hirenkumar Mansukhlal Marvaniya

Hirenkumar Mansukhlal Marvaniya currently holds 1 directorship: Chynops Pharma Private Limited (Director, since 04 Aug 2025).

Hirenkumar Mansukhlal Marvaniya was first appointed on 04 Aug 2025 as Director at Chynops Pharma Private Limited.

The current boards of Hirenkumar Mansukhlal Marvaniya's companies include Rajdeep Shivlalbhai Vamja (Chynops Pharma Private Limited), Sandipkumar Dipakkumar Sinojiya (Chynops Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available